About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 806072, 15 pages
http://dx.doi.org/10.1155/2013/806072
Review Article

Exploring the Ligand-Protein Networks in Traditional Chinese Medicine: Current Databases, Methods, and Applications

National Key Laboratory of Microbial Metabolism and College of Life Sciences and Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Road, Minhang District, Shanghai 200240, China

Received 24 February 2013; Revised 6 May 2013; Accepted 7 May 2013

Academic Editor: Weidong Zhang

Copyright © 2013 Mingzhu Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. E. Kaufmann, “Paul Ehrlich: founder of chemotherapy,” Nature Reviews Drug Discovery, vol. 7, no. 5, p. 373, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. G. V. Paolini, R. H. B. Shapland, W. P. van Hoorn, J. S. Mason, and A. L. Hopkins, “Global mapping of pharmacological space,” Nature Biotechnology, vol. 24, no. 7, pp. 805–815, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Keiser, B. L. Roth, B. N. Armbruster, P. Ernsberger, J. J. Irwin, and B. K. Shoichet, “Relating protein pharmacology by ligand chemistry,” Nature Biotechnology, vol. 25, no. 2, pp. 197–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. L. Hopkins, “Drug discovery: predicting promiscuity,” Nature, vol. 462, no. 7270, pp. 167–168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Vedani, M. Dobler, and M. A. Lill, “The challenge of predicting drug toxicity in silico,” Basic and Clinical Pharmacology and Toxicology, vol. 99, no. 3, pp. 195–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Klabunde and A. Evers, “GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects,” ChemBioChem, vol. 6, no. 5, pp. 876–889, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Ekins, J. Mestres, and B. Testa, “In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling,” British Journal of Pharmacology, vol. 152, no. 1, pp. 9–20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Ekins, J. Mestres, and B. Testa, “In silico pharmacology for drug discovery: applications to targets and beyond,” British Journal of Pharmacology, vol. 152, no. 1, pp. 21–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Lukman, Y. He, and S. C. Hui, “Computational methods for Traditional Chinese Medicine: a survey,” Computer Methods and Programs in Biomedicine, vol. 88, no. 3, pp. 283–294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. T. M. Ehrman, D. J. Barlow, and P. J. Hylands, “Phytochemical informatics and virtual screening of herbs used in Chinese medicine,” Current Pharmaceutical Design, vol. 16, no. 15, pp. 1785–1798, 2010. View at Scopus
  11. Y. Feng, Z. Wu, X. Zhou, Z. Zhou, and W. Fan, “Knowledge discovery in traditional Chinese medicine: state of the art and perspectives,” Artificial Intelligence in Medicine, vol. 38, no. 3, pp. 219–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Yan, J. Zhou, and Z. Xu, “Concept design of computer-aided study on traditional chinese drugs,” Journal of Chemical Information and Computer Sciences, vol. 39, no. 1, pp. 86–89, 1999. View at Scopus
  13. S. J. Haggarty, K. M. Koeller, J. C. Wong, R. A. Butcher, and S. L. Schreiber, “Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays,” Chemistry and Biology, vol. 10, no. 5, pp. 383–396, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. F. G. Kuruvilla, A. F. Shamji, S. M. Sternson, P. J. Hergenrother, and S. L. Schreiber, “Dissecting glucose signalling with diversity-oriented synthesis and small-molecule microarrays,” Nature, vol. 416, no. 6881, pp. 653–657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. T. M. Ehrman, D. J. Barlow, and P. J. Hylands, “Phytochemical databases of Chinese herbal constituents and bioactive plant compounds with known target specificities,” Journal of Chemical Information and Modeling, vol. 47, no. 2, pp. 254–263, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Qiao, T. Hou, W. Zhang, S. Guo, and X. Xu, “A 3D structure database of components from Chinese traditional medicinal herbs,” Journal of Chemical Information and Computer Sciences, vol. 42, no. 3, pp. 481–489, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Y. Chen, “TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico,” PLoS ONE, vol. 6, no. 1, Article ID e15939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Chen, H. Zhou, Y. B. Liu et al., “Database of traditional Chinese medicine and its application to studies of mechanism and to prescription validation,” British Journal of Pharmacology, vol. 149, no. 8, pp. 1092–1103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. X.-B. Qiao, T.-J. Hou, H.-D. Yu, and X.-J. Xu, “Research and development of traditional Chinese medicine drugs,” Acta Physico-Chimica Sinica, vol. 18, pp. 394–398, 2002.
  20. X. Fang, L. Shao, H. Zhang, and S. Wang, “CHMIS-C: a comprehensive herbal medicine information system for cancer,” Journal of Medicinal Chemistry, vol. 48, no. 5, pp. 1481–1488, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Shen, X. Xu, F. Cheng et al., “Virtual screening on natural products for discovering active compounds and target information,” Current Medicinal Chemistry, vol. 10, no. 21, pp. 2327–2342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Lei and J. Zhou, “A marine natural product database,” Journal of Chemical Information and Computer Sciences, vol. 42, no. 3, pp. 742–748, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Cheng, S. A. Best, K. M. Merz, and C. H. Reynolds, “GB/SA water model for the Merck molecular force field (MMFF),” Journal of Molecular Graphics and Modelling, vol. 18, no. 3, pp. 273–282, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Bender and R. C. Glen, “Molecular similarity: a key technique in molecular informatics,” Organic and Biomolecular Chemistry, vol. 2, no. 22, pp. 3204–3218, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Willett, Similarity and Clustering in Chemical Information Systems, Chemometrics Series, Research Studies Press, New York, NY, USA, 1987.
  26. P. Willett, “Searching techniques for databases of two- and three-dimensional chemical structures,” Journal of Medicinal Chemistry, vol. 48, no. 13, pp. 4183–4199, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Willett, “Similarity-based virtual screening using 2D fingerprints,” Drug Discovery Today, vol. 11, no. 23-24, pp. 1046–1053, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. E. van der Horst, J. E. Peironcely, A. P. IJzerman et al., “A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization,” BMC Bioinformatics, vol. 11, article 316, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Keiser, V. Setola, J. J. Irwin et al., “Predicting new molecular targets for known drugs,” Nature, vol. 462, no. 7270, pp. 175–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. A. J. DeGraw, M. J. Keiser, J. D. Ochocki, B. K. Shoichet, and M. D. Distefano, “Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs,” Journal of Medicinal Chemistry, vol. 53, no. 6, pp. 2464–2471, 2010. View at Publisher · View at Google Scholar
  31. J. S. Mason, A. C. Good, and E. J. Martin, “3-D pharmacophores in drug discovery,” Current Pharmaceutical Design, vol. 7, no. 7, pp. 567–597, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Maclean, J. J. Baldwin, V. T. Ivanov, et al., “Glossary of terms used in combinatorial chemistry,” Journal of Combinatorial Chemistry, vol. 2, no. 6, pp. 562–578, 2000. View at Publisher · View at Google Scholar
  33. T. Langer and R. D. Hoffmann, Pharmacophores and Pharmacophore Searches, Wiley-VCH, Weinheim, Germany; John Wiley & Sons, Chichester, UK, 2006.
  34. M. C. Nicklaus, N. Neamati, H. Hong et al., “HIV-1 integrase pharmacophore: discovery of inhibitors through three- dimensional database searching,” Journal of Medicinal Chemistry, vol. 40, no. 6, pp. 920–929, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Koide, T. Hasegawa, A. Takahashi et al., “Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships,” Journal of Medicinal Chemistry, vol. 45, no. 21, pp. 4629–4638, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. A. K. Debnath, “Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors,” Journal of Medicinal Chemistry, vol. 46, no. 21, pp. 4501–4515, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Kurogi, K. Miyata, T. Okamura et al., “Discovery of novel mesangial cell proliferation inhibitors using a three-dimensional database searching method,” Journal of Medicinal Chemistry, vol. 44, no. 14, pp. 2304–2307, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Wolber and T. Langer, “LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters,” Journal of Chemical Information and Modeling, vol. 45, no. 1, pp. 160–169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. Rollinger, “Accessing target information by virtual parallel screening—the impact on natural product research,” Phytochemistry Letters, vol. 2, no. 2, pp. 53–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. J. M. Rollinger, D. Schuster, B. Danzl et al., “In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens,” Planta Medica, vol. 75, no. 3, pp. 195–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Sharples, “Factors affecting the binding of tricyclic tranquillizers and antidepressants to human serum albumin,” Journal of Pharmacy and Pharmacology, vol. 28, no. 2, pp. 100–105, 1976. View at Scopus
  42. R. P. Verma and C. Hansch, “An approach toward the problem of outliers in QSAR,” Bioorganic and Medicinal Chemistry, vol. 13, no. 15, pp. 4597–4621, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Polanski, A. Bak, R. Gieleciak, and T. Magdziarz, “Modeling robust QSAR,” Journal of Chemical Information and Modeling, vol. 46, no. 6, pp. 2310–2318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Kurup, “C-QSAR: a database of 18,000 QSARS and associated biological and physical data,” Journal of Computer-Aided Molecular Design, vol. 17, no. 2–4, pp. 187–196, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Hansch, D. Hoekman, A. Leo, D. Weininger, and C. D. Selassie, “Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology,” Chemical Reviews, vol. 102, no. 3, pp. 783–812, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. B. K. Shoichet, “Virtual screening of chemical libraries,” Nature, vol. 432, no. 7019, pp. 862–865, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Klebe, “Virtual ligand screening: strategies, perspectives and limitations,” Drug Discovery Today, vol. 11, no. 13-14, pp. 580–594, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Lengauer and M. Rarey, “Computational methods for biomolecular docking,” Current Opinion in Structural Biology, vol. 6, no. 3, pp. 402–406, 1996. View at Publisher · View at Google Scholar · View at Scopus
  49. D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, “Docking and scoring in virtual screening for drug discovery: methods and applications,” Nature Reviews Drug Discovery, vol. 3, no. 11, pp. 935–949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. A. R. Leach, B. K. Shoichet, and C. E. Peishoff, “Prediction of protein-ligand interactions. Docking and scoring: successes and gaps,” Journal of Medicinal Chemistry, vol. 49, no. 20, pp. 5851–5855, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Manoharan, R. S. K. Vijayan, and N. Ghoshal, “Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies,” Journal of Computer-Aided Molecular Design, vol. 24, no. 10, pp. 843–864, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. A. C. Cheng, R. G. Coleman, K. T. Smyth et al., “Structure-based maximal affinity model predicts small-molecule druggability,” Nature Biotechnology, vol. 25, no. 1, pp. 71–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Evers, H. Gohlke, and G. Klebe, “Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials,” Journal of Molecular Biology, vol. 334, no. 2, pp. 327–345, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. G. P. A. Vigers and J. P. Rizzi, “Multiple active site corrections for docking and virtual screening,” Journal of Medicinal Chemistry, vol. 47, no. 1, pp. 80–89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. Z. Gao, H. Li, H. Zhang et al., “PDTD: a web-accessible protein database for drug target identification,” BMC Bioinformatics, vol. 9, article 104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. X. Fradera and J. Mestres, “Guided docking approaches to structure-based design and screening,” Current Topics in Medicinal Chemistry, vol. 4, no. 7, pp. 687–700, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. J. C. Clemente, L. Govindasamy, A. Madabushi et al., “Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor,” Acta Crystallographica Section D: Biological Crystallography, vol. 62, no. 3, pp. 246–252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. B. A. Grzybowski, A. V. Ishchenko, C. Y. Kim et al., “Combinatorial computational method gives new picomolar ligands for a known enzyme,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 3, pp. 1270–1273, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Bissantz, “Conformational changes of G protein-coupled receptors during their activation by agonist binding,” Journal of Receptors and Signal Transduction, vol. 23, no. 2-3, pp. 123–153, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Z. Chen and D. G. Zhi, “Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule,” Proteins, vol. 43, no. 2, pp. 217–226, 2001. View at Publisher · View at Google Scholar
  61. Y. Z. Chen and C. Y. Ung, “Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach,” Journal of Molecular Graphics and Modelling, vol. 20, no. 3, pp. 199–218, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Zahler, S. Tietze, F. Totzke et al., “Inverse in silico screening for identification of kinase inhibitor targets,” Chemistry and Biology, vol. 14, no. 11, pp. 1207–1214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. M. L. MacDonald, J. Lamerdin, S. Owens, et al., “Identifying off-target effects and hidden phenotypes of drugs in human cells,” Nature Chemical Biology, vol. 2, no. 6, pp. 329–337, 2006. View at Publisher · View at Google Scholar
  64. W. N. Gao, D. Q. Wei, Y. Li et al., “Agaritine and its derivatives are potential inhibitors against HIV proteases,” Medicinal Chemistry, vol. 3, no. 3, pp. 221–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Zheng, D. Q. Wei, R. Zhang, C. Wang, H. Wei, and K. C. Chou, “Screening for new agonists against Alzheimer's disease,” Medicinal Chemistry, vol. 3, no. 5, pp. 488–493, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Wei, R. Zhang, C. Wang et al., “Molecular insights of SAH enzyme catalysis and implication for inhibitor design,” Journal of Theoretical Biology, vol. 244, no. 4, pp. 692–702, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Q. Wang, Q. S. Du, K. Zhao, A. X. Li, D. Q. Wei, and K. C. Chou, “Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy,” Amino Acids, vol. 33, no. 1, pp. 129–135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Q. Wei, R. Zhang, Q. S. Du et al., “Anti-SARS drug screening by molecular docking,” Amino Acids, vol. 31, no. 1, pp. 73–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Gong, L. Li, J. F. Wang, F. Cheng, D. Q. Wei, and K. C. Chou, “Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design,” Medicinal Chemistry, vol. 5, no. 3, pp. 242–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. R. X. Gu, H. Gu, Z. Y. Xie et al., “Possible drug candidates for Alzheimer's disease deduced from studying their binding interactions with α7 nicotinic acetylcholine receptor,” Medicinal Chemistry, vol. 5, no. 3, pp. 250–262, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. S. G. Chen, R.-X. Gu, H. Dai, and D.-Q. Wei, “Virtual screening for alpha7 nicotinic acetylcholine receptor for treatment of Alzheimer's disease,” Journal of Molecular Graphics and Modelling, vol. 39, pp. 98–107, 2013. View at Publisher · View at Google Scholar
  72. H. R. Arias, R. X. Gu, D. Feuerbach, B. B. Guo, Y. Ye, and D. Q. Wei, “Novel positive allosteric modulators of the human α7 nicotinic acetylcholine receptor,” Biochemistry, vol. 50, no. 23, pp. 5263–5278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. T. M. Mitchell, Machine Learning, McGraw-Hill Series in Computer Science, McGraw-Hill, New York, NY, USA, 1997.
  74. H. Strömbergsson and G. J. Kleywegt, “A chemogenomics view on protein-ligand spaces,” BMC Bioinformatics, vol. 10, supplement 6, article S13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. L. J. Jensen and A. Bateman, “The rise and fall of supervised machine learning techniques,” Bioinformatics, vol. 27, no. 24, pp. 3331–3332, 2011. View at Publisher · View at Google Scholar
  76. Nidhi, M. Glick, J. W. Davies, and J. L. Jenkins, “Prediction of biological targets for compounds using multiple-category bayesian models trained on chemogenomics databases,” Journal of Chemical Information and Modeling, vol. 46, no. 3, pp. 1124–1133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. F. Nigsch, N. J. M. Macaluso, J. B. O. Mitchell, and D. Zmuidinavicius, “Computational toxicology: an overview of the sources of data and of modelling methods,” Expert Opinion on Drug Metabolism and Toxicology, vol. 5, no. 1, pp. 1–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. T. van Laarhoven, S. B. Nabuurs, and E. Marchiori, “Gaussian interaction profile kernels for predicting drug-target interaction,” Bioinformatics, vol. 27, no. 21, pp. 3036–3043, 2011.
  79. Q. Li and L. Lai, “Prediction of potential drug targets based on simple sequence properties,” BMC Bioinformatics, vol. 8, article 353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. Yamanishi, M. Araki, A. Gutteridge, W. Honda, and M. Kanehisa, “Prediction of drug-target interaction networks from the integration of chemical and genomic spaces,” Bioinformatics, vol. 24, no. 13, pp. i232–i240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. K. Bleakley and Y. Yamanishi, “Supervised prediction of drug-target interactions using bipartite local models,” Bioinformatics, vol. 25, no. 18, pp. 2397–2403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. W. Yu, X. Cheng, Z. Li, and Z. Jiang, “Predicting drug-target interactions based on an improved semi-supervised learning approach,” Drug Development Research, vol. 72, no. 2, pp. 219–224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. N. Wale and G. Karypis, “Target fishing for chemical compounds using target-ligand activity data and ranking based methods,” Journal of Chemical Information and Modeling, vol. 49, no. 10, pp. 2190–2201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Kuhn, C. von Mering, M. Campillos, L. J. Jensen, and P. Bork, “STITCH: interaction networks of chemicals and proteins,” Nucleic Acids Research, vol. 36, no. 1, pp. D684–D688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Zhao, H.-T. Chang, Z. Liu, L. Chen, and D. Wei, “Predicting protein-ligand interactions based on chemical preference features with its application to new D-amino acid oxidase inhibitor discovery,” Current Pharmaceutical Design. In press.
  86. T. M. Ehrman, D. J. Barlow, and P. J. Hylands, “Virtual screening of Chinese herbs with random forest,” Journal of Chemical Information and Modeling, vol. 47, no. 2, pp. 264–278, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Paoletta, G. B. Steventon, D. Wildeboer, T. M. Ehrman, P. J. Hylands, and D. J. Barlow, “Screening of herbal constituents for aromatase inhibitory activity,” Bioorganic and Medicinal Chemistry, vol. 16, no. 18, pp. 8466–8470, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Zhao and S. Li, “Network-based relating pharmacological and genomic spaces for drug target identification,” PLoS ONE, vol. 5, no. 7, Article ID e11764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. S. Li and B. Zhang, “Traditional Chinese medicine network pharmacology: theory, methodology and application,” Chinese Journal of Natural Medicines, vol. 11, no. 2, pp. 110–120, 2013.
  90. G. Borkow and A. Lapidot, “Multi-targeting the entrance door to block HIV-1,” Current Drug Targets—Infectious Disorders, vol. 5, no. 1, pp. 3–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Li, V. K. W. Wong, X. Q. Yi, Y. F. Wong, H. Zhou, and L. Liu, “Matrine induces cell anergy in human jurkat T cells through modulation of mitogen-activated protein kinases and nuclear factor of activated t-cells signaling with concomitant up-regulation of anergy-associated genes expression,” Biological and Pharmaceutical Bulletin, vol. 33, no. 1, pp. 40–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. W. Lam, S. Bussom, F. Guan et al., “Chemotherapy: the four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity,” Science Translational Medicine, vol. 2, no. 45, article 45ra59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. Y. Xie, H. Zhou, Y. F. Wong, H. X. Xu, Z. H. Jiang, and L. Liu, “Study on the pharmacokinetics and metabolism of paeonol in rats treated with pure paeonol and an herbal preparation containing paeonol by using HPLC-DAD-MS method,” Journal of Pharmaceutical and Biomedical Analysis, vol. 46, no. 4, pp. 748–756, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. Z. Q. Liu, Z. H. Jiang, K. Chan, et al., “Pharmacokinetic interaction of paeoniflorin and sinomenine: pharmacokinetic parameters and tissue distribution characteristics in rats and protein binding ability in vitro,” Journal of Pharmacological Sciences, vol. 99, no. 4, pp. 381–391, 2005. View at Publisher · View at Google Scholar
  95. H. Zeng, S. Dou, J. Zhao et al., “The inhibitory activities of the components of Huang-Lian-Jie-Du-Tang (HLJDT) on eicosanoid generation via lipoxygenase pathway,” Journal of Ethnopharmacology, vol. 135, no. 2, pp. 561–568, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. L. Wang, G. B. Zhou, P. Liu et al., “Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 12, pp. 4826–4831, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. Q. Y. Zhang, J. H. Mao, P. Liu et al., “A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 9, pp. 3378–3383, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. T. M. Ehrman, D. J. Barlow, and P. J. Hylands, “In silico search for multi-target anti-inflammatories in Chinese herbs and formulas,” Bioorganic and Medicinal Chemistry, vol. 18, no. 6, pp. 2204–2218, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Gu, H. Zhang, L. Chen, S. Xu, G. Yuan, and X. Xu, “Drug-target network and polypharmacology studies of a Traditional Chinese Medicine for type II diabetes mellitus,” Computational Biology and Chemistry, vol. 35, no. 5, pp. 293–297, 2011. View at Publisher · View at Google Scholar
  100. Q. Huang, X. Qiao, and X. Xu, “Potential synergism and inhibitors to multiple target enzymes of Xuefu Zhuyu Decoction in cardiac disease therapeutics: a computational approach,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 6, pp. 1779–1783, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Li, B. Zhang, D. Jiang, Y. Wei, and N. Zhang, “Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae,” BMC Bioinformatics, vol. 11, supplement 11, article S6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. Y. Wang, L. Yu, L. Zhang, H. Qu, and Y. Cheng, “A novel methodology for multicomponent drug design and its application in optimizing the combination of active components from Chinese medicinal formula shenmai,” Chemical Biology and Drug Design, vol. 75, no. 3, pp. 318–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Wang, X. Wang, and Y. Cheng, “A computational approach to botanical drug design by modeling quantitative composition-activity relationship,” Chemical Biology and Drug Design, vol. 68, no. 3, pp. 166–172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. Q. Li, X. Li, C. Li et al., “A network-based multi-target computational estimation scheme for anticoagulant activities of compounds,” PLoS ONE, vol. 6, no. 3, Article ID e14774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. Y. Sun, R. Zhu, H. Ye, et al., “Towards a bioinformatics analysis of anti-Alzheimer's herbal medicines from a target network perspective,” Briefings in Bioinformatics, 2013. View at Publisher · View at Google Scholar
  106. J. Zhao, P. Jiang, and W. Zhang, “Molecular networks for the study of TCM pharmacology,” Briefings in Bioinformatics, vol. 11, no. 4, pp. 417–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. B. Zhang, X. Wang, and S. Li, “An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 456747, 12 pages, 2013. View at Publisher · View at Google Scholar
  108. E. Klipp, R. C. Wade, and U. Kummer, “Biochemical network-based drug-target prediction,” Current Opinion in Biotechnology, vol. 21, no. 4, pp. 511–516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. E. L. Leung, Z. W. Cao, Z. H. Jiang, H. Zhou, and L. Liu, “Network-based drug discovery by integrating systems biology and computational technologies,” Briefings in Bioinformatics, 2013. View at Publisher · View at Google Scholar
  110. T. Wang, J. Gu, J. Yuan, R. Tao, Y. Li, and S. Li, “Inferring pathway crosstalk networks using gene set co-expression signatures,” Molecular BioSystems, 2013. View at Publisher · View at Google Scholar
  111. R. Kanawong, T. Obafemi-Ajayi, T. Ma, D. Xu, S. Li, and Y. Duan, “Automated tongue feature extraction for ZHENG classification in traditional chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 912852, 14 pages, 2012. View at Publisher · View at Google Scholar
  112. A. M. Soto and C. Sonnenschein, “Emergentism as a default: cancer as a problem of tissue organization,” Journal of Biosciences, vol. 30, no. 1, pp. 103–118, 2005. View at Scopus